Bill
Bill > S1915
MA S1915
To eliminate the tax deduction for direct-to-consumer pharmaceutical marketing
summary
Introduced
03/29/2021
03/29/2021
In Committee
03/29/2021
03/29/2021
Crossed Over
Passed
Dead
12/31/2022
12/31/2022
Introduced Session
192nd General Court
Bill Summary
For legislation to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing. Revenue.
AI Summary
This bill aims to eliminate the tax deduction for direct-to-consumer pharmaceutical marketing. Specifically, it proposes to disallow the deduction described in Section 162(a) of the Internal Revenue Code, which allows businesses to deduct ordinary and necessary expenses, to the extent that this deduction applies to direct consumer advertising of prescription drugs and devices in Massachusetts. This includes media advertising, coupons, outreach and persistency programs, and any other forms of marketing or advertising directed to persons other than licensed prescribers. The bill aims to reduce the tax incentive for pharmaceutical companies to engage in direct-to-consumer marketing practices.
Committee Categories
Budget and Finance
Sponsors (2)
Last Action
Accompanied a study order, see H5250 (on 10/03/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://malegislature.gov/Bills/192/S1915 |
| Bill | https://malegislature.gov/Bills/192/S1915.pdf |
Loading...